IMMUNOME INC reports a Return on Equity (ROE) of -38.15%.

What is IMNM's dividend yield?

IMMUNOME INC offers a dividend yield of 0.00%.

What is IMNM's Quality Score?

Our AI rates IMNM's overall financial quality at 23 out of 100, based on profitability, growth, debt and earnings stability.

Is now a good time to buy IMNM?

Our AI Timing Score for IMNM is 91 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.

Which sector does IMNM belong to?

IMMUNOME INC is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange

IMNM (NASDAQ) Stock Analysis | IMMUNOME INC

Stock Check Daily update data at 8:30 AM
(Price: 2026-07-31 | FS: 2026-03-31)

IMNM AI Analysis Summary

Our AI summary for IMNM: IMMUNOME INC (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 0.00, ROE of -38.15%, a dividend yield of 0.00%. Its financial Quality Score stands at 23/100 — fundamentals below the market average. The AI Timing Score is 91/100 — multiple technical signals currently support price momentum. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.

IMNM

IMMUNOME INC

US:NASDAQ STOCK Healthcare >> Biotechnology

USD 22.76

-0.32 (-1.39%) Day Change

Watchlist Portfolio Compare Chart

0.05

D/E

-38.2%

ROE

-36.2%

ROA

0.00%

Div Yield

IMMUNOME INC
TYPE: STOCK
MARKET: NASDAQ

Compare Watchlist Myport

USD 22.76 Price -0.32 (-1.39%) Day Change	NEWS SCORE: N/A

IMNM, the overall quality is not good ( Quality = 23) but the timing to buy is ...(Sign In to See)...

Loading chart...

23 QUALITY

Signal: UNDERPERFORM

Signal Description: Company financial health is Not Good

Reason: ROE is relatively low.
ROA is relatively low.
Acceleration of ROE growth rate is below our criteria.
Historical ROE is relatively low
ROE is decreasing significantly
ROA is too relatively low compare to ROE
Acceleration of ROA growth rate is below our criteria.
Current growth of ROA was below our criteria.
Net profit margin is relatively low.
Historical net profit margin is relatively low.

88 Sign in

TIMING

Signal: OUTPERFORM

Signal Descri...: Good

Reason: Momentum indicators aligned on the daily timeframe

Unlock timing signals and detailed reasons

In details, quality factors are not good , financial health is not quite good , and ability to make profit is not quite good , ...

Quality Factors

39%

In Recommendations?	Not in any sections
Select Rate	0.00 From 30 days period
Watch Rate	0.00 From 30 days period
News Score	N/A
Magic Formula Rank by ROA	N/A
Magic Formula Rank by ROE	N/A
Magic Formula Rank by ROIC	N/A
Price	22.76
PBV / Sector	4.44 / 5.20
Earning Per Share	-1.96

PE / Sector	N/A / 19.97
PEG or PE/Growth / Sector	N/A / 1.22
Average 1M Daily Value	24.43 M GREAT
Average 1W Daily Value	16.76 M GREAT

Timing Factors

71%

MACD	SIGN IN
MACD Signal	SIGN IN
MACD Divergence	SIGN IN
RSI	SIGN IN
Stochastic Oscillator K	SIGN IN
Stochastic Oscillator D	SIGN IN
ADX	SIGN IN
Avg 5 day Timing Score	SIGN IN

Financial Health

50%

DE / Sector	SIGN IN
DE Average / Sector	SIGN IN
DE Change Average (%) / Sector	SIGN IN
Current Ratio / Sector	SIGN IN
Current Ratio Average / Sector	SIGN IN
Current Ratio Change Average (%) / Sector	SIGN IN
Quick Ratio / Sector	SIGN IN
Quick Ratio Average / Sector	SIGN IN
Quick Ratio Change Average (%) / Sector	SIGN IN
FCF/Share / Sector	SIGN IN
FCF/Share Average / Sector	SIGN IN
FCF/Share Change Average (%) / Sector	SIGN IN

Ability to Make Profit

52%

GPM (%) / Sector	SIGN IN
GPM Average (%) / Sector	SIGN IN
GPM Change Average (%) / Sector	SIGN IN
OPM (%) / Sector	SIGN IN
OPM Average (%) / Sector	SIGN IN
OPM Change Average (%) / Sector	SIGN IN
NPM (%) / Sector	-5,593.85 / 98.71
NPM Average (%) / Sector	-2,642.58 / -1,721.76
NPM Change Average (%) / Sector	109.85 / 5,211.62 GREAT
Asset Turnover / Sector	SIGN IN
Asset Turnover Average / Sector	SIGN IN
Asset Turnover Change Average (%) / Sector	SIGN IN
ROA (%) / Sector	-36.24 / 27.02
ROA Average (%) / Sector	-82.92 / -368.17
ROA Change Average (%) / Sector	-10.37 / 5,404.12
ROE (%) / Sector	-38.15 / 3.47
ROE Average (%) / Sector	-108.80 / 6.51
ROE Change Average (%) / Sector	-10.91 / 2,128.13
ROIC (%) / Sector	SIGN IN
ROIC Average (%) / Sector	SIGN IN
ROIC Change Average (%) / Sector	SIGN IN

Return to Investors

Dividend (%) / Sector	N/A / 0.04
Dividend Average (%) / Sector	N/A / 17.04
Dividend Change Average (%) / Sector	N/A / -1.75

Registration Details

Analyze Date	2026-08-01 08:00:00
Symbol	IMNM
Name	IMMUNOME INC
Sector	Healthcare >> Biotechnology
Market	NASDAQ
Listed Shares	113.25 M
Par Value	N/A
Calculated From	Quarter
Sign	N/A
Market Cap (M.USD) / Sector Average	2,613.82 / 9,903.94

News, Concensus, ...

Estimation Consensus	See at WSJ.com
Full details	See at WSJ.com
Chart	See in Chart feature
News	See at Yahoo Finance

Address: 18702 North Creek Parkway, Bothell, WA, United States, 98011

Phone: 425 939 7410

Website: https://immunome.com

Employees: 206

Sector: Healthcare >> Biotechnology

Description: Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial. It is also developing preclinical assets, including IM-3050, a fibroblast activation protein targeted radioligand therapy; and solid tumor ADC drug candidates, such as IM-1617, IM-1340, and IM-1335. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.